Top-News
Dienstag,
15.10.2019 12:45
von
PR Newswire
| Aufrufe: 209
Johnson & Johnson Reports 2019 Third-Quarter Results
In der Downing Street in London residieren die englischen Premierminister.
pixabay.com
PR Newswire
NEW BRUNSWICK, N.J., Oct. 15, 2019
NEW BRUNSWICK, N.J., Oct. 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. "Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "As we look ahead, we remain confident in the strength of our broad-based business model, which is fueled by our disciplined portfolio management, focus on transformational innovation and dedicated employees around the world who position us for success today and well into the future."
OVERALL FINANCIAL RESULTS:
| | THIRD QUARTER | | |
| ($ in Millions, except EPS) | 2019 | 2018 | % Change |
| Reported Sales | $ 20,729 | $ 20,348 | 1.9% |
| Net Earnings | 4,833 | 3,934 | 22.9 |
| EPS (diluted) | $ 1.81 | $ 1.44 | 25.7 |
| | | | |
| Non-GAAP* | THIRD QUARTER | | |
| ($ in Millions, except EPS) | 2019 | 2018 | % Change |
| Operational Sales1,2 | n/a | n/a | 3.2% |
| Adjusted Operational Sales1,3 | n/a | n/a | 5.2 |
| Adjusted Net Earnings1,4 | 5,672 | 5,590 | 1.5 |
| Adjusted EPS (diluted)1,4 | $ 2.12 | $ 2.05 | 3.4 |
| 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |||
| 2 Excludes the impact of translational currency | |||
| 3 Excludes the net impact of acquisitions and divestitures and translational currency | |||
| 4 Excludes intangible amortization expense and special items | |||
REGIONAL SALES RESULTS:
| | THIRD QUARTER | % Change | ||||
|
| 2019 | 2018 |
|
|
| Adjusted |
| U.S. | $ 10,791 | $ 10,664 | 1.2% | 1.2 | - | 3.4 |
| International | 9,938 | 9,684 | 2.6 | 5.4 | (2.8) | 7.3 |
| Worldwide | $ 20,729 | $ 20,348 | 1.9% | 3.2 | (1.3) | 5.2 |
| 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | ||||||
| 2 Excludes the impact of translational currency | ||||||
| 3 Excludes the net impact of acquisitions and divestitures and translational currency | ||||||
| Note: values may have been rounded | ||||||
SEGMENT SALES RESULTS:
| | THIRD QUARTER | % Change | ||||
|
| 2019 | 2018 |
| Operational1,2 | Currency | Adjusted |
| Consumer | $ 3,469 | $ 3,415 | 1.6% | 3.3 | (1.7) | 1.3 |
| Pharmaceuticals Werbung Mehr Nachrichten zur Johnson & Johnson Corp. Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||||||
